Xilio Therapeutics Scheduled to Announce Third Quarter 2026 Financial Results
Xilio Therapeutics, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 5, 2026.
Stocks · News reference
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501
Xilio Therapeutics has initiated dosing in its Phase 1/2 clinical trial for XTX501, a bispecific antibody fusion protein targeting metastatic non-small cell lung cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
Xilio Therapeutics, Inc. announced that company management will participate in a presentation at the Stifel 2026 Healthcare Conference on November 10, 2026.
Raymond James Initiates Coverage on Xilio Therapeutics with Outperform Rating
Raymond James has initiated coverage on Xilio Therapeutics, assigning the company an 'Outperform' rating and a price target of $16.00 per share.
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted stock options to new employees and newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. on October 1, 2026. The company granted 100,895 shares to two new employees and 105,000 shares to Dr. Houvras at an exercise price of $8.91 per share, with a standard vesting schedule of 25% after one year followed by 36 monthly installments.
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share